Treatment of hepatitis C using direct-acting antiviral (DAA) agents in patients undergoing liver transplantation

Treatment of hepatitis C using direct-acting antiviral (DAA) agents in patients undergoing liver transplantation

.

Saved in:

Bibliographic Details
Main Authors:	V. E. Syutkin, A. A. Salienko, M. S. Novruzbekov
Format:	Article
Language:	English
Published:	N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department 2016-02-01
Series:	Трансплантология (Москва)
Online Access:	https://www.jtransplantologiya.ru/jour/article/view/75
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience)
by: M. Sh. Khubutiya, et al.
Published: (2016-02-01)

The use of sofosbuvir for the treatment of recurrent hepatitis C after liver transplantation
by: M. Sh. Khubutiya, et al.
Published: (2017-03-01)

POSSIBILITIES OF HEPATITIS C ANTIVIRAL TREATMENT IN LIVER TRANSPLANT RECIPIENTS
by: V. E. Syutkin, et al.
Published: (2011-06-01)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01)

TREATMENT OF HEPATITIS C WITHOUT INTERFERON IN PATIENTS UNDERGOING LIVER TRANSPLANTATION
by: M. Sh. Khubutia, et al.
Published: (2015-10-01)

Treatment of the chronic hepatitis C complicated by mixed cryoglobulinemia with direct-acting antiviral agents
by: N. V. Dunaeva, et al.
Published: (2018-12-01)

Efficiency of Antiviral Therapy for Recurrence of Chronic Hepatitis C in Patients Undergoing Liver Transplantation
by: A. A. Sukhoruk, et al.
Published: (2014-09-01)

CMV-infection in patients after liver transplantation
by: M. Sh. Khubutiya, et al.
Published: (2016-02-01)

Relapse of autoimmune diseases after liver transplantation
by: V. E. Syutkin, et al.
Published: (2022-12-01)

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
by: Fei Xiao, et al.
Published: (2014-05-01)

Treatment of hepatitis C in liver transplant recipients in the Moscow Center for Liver Transplantation within 10 years
by: M. Sh. Khubutia, et al.
Published: (2016-01-01)

Evaluation of direct-acting antiviral agents impact on liver biomarkers in patients with type-2 diabetes and hepatitis C virus infection
by: Irina Duport-Dodot, et al.
Published: (2024-06-01)

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature
by: Olga H. Orasan, et al.
Published: (2019-10-01)

Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?
by: Zhitao Wang, et al.
Published: (2025-07-01)

An ODEs multiscale model with cell proliferation for hepatitis C virus infection treated with direct acting antiviral agents
by: Hesham A. Elkaranshawy, et al.
Published: (2024-12-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

Direct-Acting-Antivirals Anti-hepatitis C Virus in Renal Transplant Patients: Relevance of Pharmacologic Interaction
by: Maurizio Salvadori, et al.
Published: (2020-08-01)

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
by: Sourabh Sharma, et al.
Published: (2018-01-01)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
by: Eric R. Yoo, et al.
Published: (2016-01-01)

Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease
by: Mahmoud Saif-Al-Islam, et al.
Published: (2021-01-01)

Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience
by: Mohamad M. Alkadi, et al.
Published: (2021-03-01)

Liver stiffness and spleen stiffness predict distinct liver-related events after hepatitis C eradication with direct-acting antivirals
by: Sheng-Hung Chen, et al.
Published: (2024-12-01)

Self-reported experience in patients treated with Hepatitis C direct acting antivirals
by: Irene Cañamares Orbis, et al.
Published: (2016-12-01)

Medicaid and Medicare Utilization of Direct-Acting Antiviral Medications for Patients With Hepatitis C
by: Xiaohan Ying, et al.
Published: (2025-01-01)

Vaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causes
by: V. E. Syutkin, et al.
Published: (2018-08-01)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
by: Peter Karayiannis
Published: (2012-01-01)

Antiviral therapy of hepatitis C with 1 genotype after liver transplantation
by: O. M. Tsiroulnikova, et al.
Published: (2018-09-01)

Outcomes of liver transplantation in the era of modern antiviral therapy for hepatitis C
by: K. Yu. Kokina, et al.
Published: (2021-04-01)

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
by: Carlo Smirne, et al.
Published: (2024-12-01)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
by: Yosra Zaimi, et al.
Published: (2021-10-01)

Effects of Various Direct-acting Antivirals in the Quality of Life of Patients with Chronic Hepatitis C
by: Hatun ÖZTÜRK ÇERİK, et al.
Published: (2021-12-01)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
by: Adina Turcu-Stiolica, et al.
Published: (2024-11-01)

The effect of early everolimus administration on the renal function while reducing the dosage of calcineurin inhibitors in liver transplant recipients in a long-term follow-up
by: V. E. Syutkin, et al.
Published: (2021-06-01)

Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
by: Chen-Hua Liu, et al.
Published: (2025-04-01)

Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy
by: Xiping Ran, et al.
Published: (2025-02-01)

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
by: Rakesh Aggarwal, et al.
Published: (2017-01-01)

Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics
by: Hossain M.S. Sazzad, et al.
Published: (2025-05-01)

The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation
by: О. M. Tsiroulnikova, et al.
Published: (2019-01-01)

Recommendations for the prevention and treatment of hepatitis B and C infection in patients on the waiting list for liver transplantation and in liver transplant recipients
by: M. Sh. Khubutiya, et al.
Published: (2020-09-01)